News

FASTEN Data Offers an Early Look at Ladera Closure

FASTEN Data Offers an Early Look at Ladera Closure

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address a stubborn procedural problem: sealing a much larger arterial puncture without creating a fresh mess.

A Promising Result, Not a Victory Lap

FASTEN was prospective, multicenter, and conducted across six sites in Australia, Belgium, and the Netherlands. Those are sensible ingredients for an early device study. An independent clinical events committee adjudicated the primary safety endpoint, which matters. Device makers should not be grading their own homework on complications if anyone wants the result taken seriously.

The reported safety figure is strong: 98.1% freedom from major target-limb access-site complications through 30 days, listed as 52 of 53 evaluable patients. Freedom from minor access-site complications was also 98.1%, again 52 of 53. Mean time to hemostasis was 0.5 plus or minus 2.0 minutes, while the median was zero minutes. In plain English, the system appears to have achieved bleeding control immediately in a substantial share of cases.

That is the kind of operational outcome physicians notice. TAVR has become more routine, but large-bore femoral access remains a real vulnerability. Bleeding, vascular injury, rescue maneuvers, and longer recovery can erase some of the elegance of a minimally invasive valve procedure. Nobody in a cath lab needs a lecture about that.

The Numbers That Deserve a Second Read

Still, this is a 55-patient, single-arm study. There is no randomized comparison against the established practice of using multiple small-bore suture closure devices, nor against an implant-based closure approach. Without that, FASTEN cannot tell us whether Ladera is better, merely that the observed results were encouraging in this selected cohort.

  • Technical success was 94.5%, or 52 of 55 patients.
  • Treatment success was 94.3%, or 50 of 53 evaluable patients.
  • Mean time to ambulation was 14.3 plus or minus 14.5 hours.
  • The primary safety and minor-complication results use 53-patient denominators, despite 55 total enrollments.

That denominator shift is not necessarily alarming; clinical studies often have endpoint-specific evaluability rules. But it is exactly the sort of detail that ought to be explained clearly in a fuller scientific presentation or publication. A 98.1% rate sounds crisp, yet one event in a small study moves the percentage quite a bit. This is why investors and clinicians alike should resist treating a rounded headline statistic like a final verdict.

Why the Design Could Matter in Practice

Ladera's pitch is straightforward enough. Its device is designed for 10F to 24F arteriotomies with one suture-mediated system, using either a pre-close or post-close approach. It deploys two parallel sutures simultaneously and maintains guidewire access during closure. The retained guidewire is not a marketing garnish. When closure gets complicated, preserving a bailout route can be a meaningful procedural advantage.

Current large-bore workflows can require two or more devices intended for smaller punctures, or a system that leaves material inside the artery. The argument for a single-device suture solution is practical: fewer steps, less hardware, no large implant left behind, and potentially a more repeatable workflow. Of course, “potentially” is doing some work there. Ease of use across many operators and anatomies has to be proved beyond an early multicenter experience.

Fast hemostasis is useful, but reproducible closure under real-world pressure is the bar that matters.

What the Sector Should Watch Next

The backdrop is favorable. Transfemoral TAVR/TAVI continues expanding, and larger-bore transcatheter procedures are an important cardiovascular device category. A closure technology that reliably trims access-site trouble could have genuine clinical and commercial relevance. Yet the company is private, and the Ladera Large Bore Closure System remains investigational under federal law and is not available for sale anywhere.

That last fact should cool any urge to sprint ahead of the evidence. There is no sales ramp to model, no approved-market share to claim, and no indication here of timing for regulatory clearance. The next useful proof points would be larger cohorts, transparent accounting for all enrolled patients, comparison with current closure strategies, and evidence that results hold up outside experienced study sites.

For the moment, FASTEN reads like a credible early signal rather than a finished story. Ladera has put forward a device concept that fits a visible clinical need, and the reported 30-day safety and hemostasis data are plainly encouraging. The hard part, as usual in medtech, is carrying that tidy trial-room result into broader, less forgiving clinical reality.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 220

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 342

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 297

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 494

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 258

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 344

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 423

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 562

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 585

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 354

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading

Top 5 Most Recently Viewed Articles

Revolutionizing Breast Aesthetics: Embracing Natural Beauty

Updated Category News Views 467

Global Surgeons Advocate for Natural Breast Aesthetics In a groundbreaking initiative, a coalition of prominent plastic surgeons has introduced a new standard for breast augmentation emphasizing 'Natural Breast Beauty'. This initiative, presented at an international symposium in Milan, arose from increasing concerns regarding aesthetically unpleasing results and the...

Continue Reading
Pony AI Receives Strong Buy Ratings from Top Financial Firms

Updated Category News Views 189

Pony AI's Promising Future with Top Ratings Pony AI has recently come into the spotlight after receiving a positive assessment from two major financial institutions, Bank of America and Goldman Sachs. Both firms have initiated coverage on the company, marking it with a favorable ‘buy’ rating. Bank of America has set an ambitious price target of $18, indicating a...

Continue Reading
Rapport Therapeutics: Insights on Neuropsychiatry Conference Participation

Updated Category News Views 116

Rapport Therapeutics at the Neuropsychiatry Summit BOSTON and SAN DIEGO – Rapport Therapeutics, Inc. (NASDAQ: RAPP), a clinical-stage biotechnology company, is making headway in the realm of neurological and psychiatric disorders through its small molecule precision medicines. The company is gearing up to participate in the upcoming TD Cowen's 5th Annual Novel...

Continue Reading
Innovative Credit Card Security Solution by InventHelp Inventor

Updated Category News Views 228

Innovative Credit Card Security Solution An inventor has come up with a groundbreaking idea to guard credit and debit card users against unauthorized transactions. This invention, termed the CREDIT CARD SECURITY LOCK, aims to provide an extra layer of protection, ensuring that only the legitimate cardholder can access their funds. Revolutionizing Payment Security This...

Continue Reading
Polling Insights: Vance and Walz's Debate Performance Analyzed

Updated Category News Views 87

Debate Highlights Between Vance and Walz In a recent debate that captured public attention, Minnesota Governor Tim Walz and Senator J.D. Vance (R-Ohio) engaged in a spirited discussion that left many viewers with strong opinions. According to flash polls conducted by CNN, Vance emerged slightly ahead in the eyes of debate watchers. Polling Results Breakdown The debate was...

Continue Reading